Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 340, Issue 6, pp 671–678 | Cite as

Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors

  • Rahel Burde
  • Roland Seifert
  • Armin Buschauerz
  • Günter Schultz
Article

Summary

The effects of prostaglandin E1 (PGE1) and histamine on activation of superoxide (O22/su−) formation, exocytosis of β-glucuronidase and aggregation in human neutrophils and HL-60 leukemic cells were studied. PGE1, histamine and impromidine, a potent H2-agonist, inhibited O2 formation in neutrophils induced by the chemotactic peptide, N-formyl-l,-methionyl-l-leucyl-l-phenylalanine (fMet-Leu-Phe) with IC50 values of 0.5 µM, 8 µM and 2 µM, respectively. The full H1-agonist and weak partial H2-agonist, betahistine, was much less potent and effective than histamine. Dibutyryl cyclic AMP and forskolin mimicked the effects of histamine and PGE1, on O2 formation. The H2-antagonist, famotidine, competitively reversed histamine-induced inhibition of O2 formation with a pA2 value of 7.5. Histamine inhibited O2 formation when added prior to or after fMet-Leu-Phe. fMet-Leu-Phe-induced aggregation and release of β-glucuronidase in neutrophils were less sensitive to inhibition by PGE1, histamine, dibutyryl cyclic AMP and forskolin thanOZ formation. The inhibitor of cyclic AMP-specific phosphodiesterase, rac-4-(3-butoxy4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724), additively enhanced the inhibitory effects of histamine and PGE1, on the above cell functions. In HL-60 cells differentiated by dimethyl sulfoxide or dibutyryl cyclic AMP, histamine, impromidine and PGE1, but not betahistine inhibited fMet-Leu-Phe-induced O2 formation as well. Our data suggest that histamine inhibits activation of neutrophils and HL-60 cells via H2-receptors through activation of adenylyl cyclase and increased formation of cyclic AMP. As stimulated basophils and mast cells release high quantities of histamine, this intercellular signal molecule may play an inhibitory role in the activation of cytotoxic functions of myeloid cells.

Key words

Superoxide formation Exocytosis Aggregation Adenylyl cyclase Histamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Absolom DR (1986) Basic methods for the study of phagocytosis. Methods Enzymol 132:95–180Google Scholar
  2. Arrang J-M, Garbarg M, Schwartz J-C (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302:832–837Google Scholar
  3. Arrang J-M, Garbarg M, Quach TT, Tuong MDT, Yerimian E, Schwartz J-C (1985) Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 111:73–84Google Scholar
  4. Arrang J-M, Garbarg M, Lancelot J-C, Lecomte J-M, Pollard H, Robba M, Schunack W, Schwartz J-C (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117–123Google Scholar
  5. Ash ASF, Schild HO (1966) Receptors mediating some actions of histamine. Br J Pharmacol Chemother 27:427–439Google Scholar
  6. Barovsky K, Brooker G (1985) Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling. Mol Pharmacol 28:502–507Google Scholar
  7. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM (1972) Definition and antagonism of histamine Hz-receptors. Nature 236:385–390Google Scholar
  8. Buschauer A, Schunack, W, Arrang J-M, Garbarg M, Schwartz JC, Young JM (1989) Histamine receptors. In: Williams M, Glennon RA, Timmermans PBMWM (eds) Clinical Pharmacology Vol 13: Receptor Pharmacology and Function. New York, Basel, pp 293–348Google Scholar
  9. Chaplinski TJ, Niedel JE (1982) Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. J Clin Invest 70:953–964Google Scholar
  10. Dewald B, Baggiolini M (1985) Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4. Biochem Biophys Res Commun 128:297–304Google Scholar
  11. Diaz P, Jones DG, Kay AB (1979) Histamine-coated particles generate superoxide (O2 ) and chemiluminescence in alveolar macrophages. Nature 278:454–456Google Scholar
  12. Dubyak GR, Cowen DS, Meuller LM (1988) Activation of inositol phospholipid breakdown in HL-60 cells by P2-purinergic receptors for extracellular ATP. Evidence for mediation by both pertussis toxin-sensitive and pertussis toxin-insensitive mechanisms. J Biol Chem 263:18108–18117Google Scholar
  13. Durant GJ, Duncan WAM, Ganellin CR, Parsons ME, Blakemore RC, Rasmussen AC (1978) Impromidine (SK & F 92676) is a very potent and specific agonist for histamine HZ receptors. Nature 276:403–405Google Scholar
  14. Durant GJ, Ganellin CR, Hills DW, Miles PD, Parsons ME, Pepper ES, White GR (1985) The histamine H2 receptor agonist impromidine: Synthesis and structure-activity considerations. J Med Chem 28:1414–1422Google Scholar
  15. Ganellin CR (1978) Chemistry and structure-activity relationships of HZ-receptor antagonists. In: Rocha e Silva M (ed) Handbook of experimental pharmacology, vol XVIII/2. Histamine II and anti-histaminics. Chemistry, metabolism and physiological and pharmacological actions. Springer, Berlin Heidelberg New York, pp 251–294Google Scholar
  16. Ganellin CR (1982) Chemistry and structure-activity relationship of drugs acting at histamine receptors. In: Ganellin CR, Parsons (eds) Pharmacology of histamine receptors. Wright, Bristol, pp 10–102Google Scholar
  17. Gespach C, Abita J-P (1982) Human polymorphonuclear neutrophils. Pharmacological characterization of histamine receptors mediating the elevation of cyclic AMP. Mol Pharmacol 21:78–85Google Scholar
  18. Gespach C, Saal F, Cost H, Abita J-P (1982) Identification and characterization of surface receptors for histamine in the human promyelocytic leukemia cell line HL-60. Comparison with human peripheral neutrophils. Mol Pharmacol 22:547–553Google Scholar
  19. Gryglewski RJ, Szczeklik A, Wandzilak M (1987) The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 24:4209–4213Google Scholar
  20. Henderson WR, Kaliner M (1978) Immunologic and nonimmunologic generation of superoxide from mast cells and basophils. J Clin Invest 61:187–196Google Scholar
  21. Jesaitis AJ, Tolley JO, Allen RA (1986) Receptor-cytoskeleton interaction and membrane traffic may regulate chemoattractant-induced superoxide production in human granulocytes. J Biol Chem 261:13 662–13 669Google Scholar
  22. Kitagawa S, Takaku F, Sakamoto S (1980) Serine protease inhibitors inhibit superoxide production by human basophils stimulated by anti-IgE. Biochem Biophys Res Commun 95:801–806Google Scholar
  23. Korchak HM, Wilkenfeld C, Rich AM, Radin AR, Vienne K, Rutherford LE (1984) Stimulus response coupling in the human neutrophil. Differential requirements for receptor occupancy in neutrophil responses to a chemoattractant. J Biol Chem 259:7439–7445Google Scholar
  24. Kuhns DB, Wright DG, Nath J, Kaplan SS, Basford RE (1988) ATP induces transient elevations of [Ca2+]i in human neutrophils and primes these cells for enhanced O2 generation. Lab Invest 58:448–453Google Scholar
  25. Lad PM, Goldberg BJ, Smiley PA, Olson CV (1985) Receptorspecific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils. Biochim Biophys Acta 846:286–295Google Scholar
  26. Malech HL, Gallin MD (1987) Neutrophils in human disease. New Engl J Med 317:687–694Google Scholar
  27. Markert M, Andrews PC, Babior BM (1984) Measurement of O2 production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Methods Enzymol 105:358–365Google Scholar
  28. Metha JL, Lawson D, Metha P (1988) Modulation of human neutrophil superoxide production by selective thromboxane synthetase inhibitor U63,557A. Life Sci 43:923–928Google Scholar
  29. Nauta WT, Rekker RF (1978) Structure-activity relationships of H1-receptor antagonists. In: Rocha e Silva M (ed) Handbook of experimental pharmacology. Vol. XVIII/2. Histamine II and anti-histaminics. Chemistry, metabolism and physiological and pharmacological actions. Springer, Berlin Heidelberg New York, pp 215–249Google Scholar
  30. Owen DAA (1987) Inflammation — histamine and 5-hydroxytryptamine. Br Med Bull 43:256–269Google Scholar
  31. Plaut M, Lichtenstein M (1982) Histamine and immune response. In: Ganellin CR, Parsons ME (eds) Pharmacology of histamine receptors. Wright, Bristol, pp 392–435Google Scholar
  32. Puustinen T, Uotila P (1984) Thromboxane formation in human polymorphonuclear leukocytes is inhibited by prednisolone and stimulated by leukotrienes B4, C4, D4 and histamine. Prostaglandins Leukotrienes Med 14:161–167Google Scholar
  33. Rossi F (1986) The O2 -forming NADPH oxidase of phagocytes: nature, mechanisms of activation and function. Biochim Biophys Acta 853:65–89Google Scholar
  34. Sandberg RR, Smolen JE (1988) Biology of disease. Early biochemical events in leukocyte activation. Lab Invest 59:300–320Google Scholar
  35. Schild HO (1947) pA, a new scale for the measurement of drug antagonism. Br J Pharmacol 2:189–206Google Scholar
  36. Schmeichel CJ, Thomas LL (1987) Methylxanthine bronchodilators potentiate multiple human neutrophil functions. J Immunol 138:1896–1903Google Scholar
  37. Schunack W (1987) What are the differences between the H2-receptor antagonists. Aliment Pharmacol Ther 1:4938–503SGoogle Scholar
  38. Schwartz J-C, Arrang J-M, Garbarg M (1986) Three classes of histamine receptors in brain. Trends Pharmacol Sci 7:24–28Google Scholar
  39. Seifert R, Schächtele C (1988) Studies with protein kinase C inhibitors presently available cannot elucidate the role of protein kinase C in the activation of NADPH oxidase. Biochem Biophys Res Commun 152:585–592Google Scholar
  40. Seifert R, Schultz G (1987) Reversible activation of NADPH oxidase in membranes of HL-60 leukemic cells. Biochem Biophys Res Commun 146:1296–1302Google Scholar
  41. Seifert R, Rosenthal W, Schultz G (1986) Guanine nucleotides stimulate NADPH oxidase in membranes of human neutrophils. FEBS Lett 205:161–165Google Scholar
  42. Seifert R, Burde R, Schultz G (1989a) Activation of NADPH oxidase by purine and pyrimidine nucleotides involves G proteins and is potentiated by chemotactic peptides. Biochem J 259:813–819Google Scholar
  43. Seifert R, Burde R, Schultz G (1989b) Lack of effect of opioid peptides, morphine and naloxone on superoxide formation in human neutrophils and HL-60 leukemic cells. Naunyn-Schmiedeberg's Arch Pharmacol 340:101–106Google Scholar
  44. Seifert R, Wenzel K, Eckstein F, Schultz G (1989c) Purine and pyrimidine nucleotides potentiate activation of NADPH oxidase and degranulation by chemotactic peptides and induce aggregation of human neutrophils via G proteins. Eur J Biochem 181:277–285Google Scholar
  45. Seligmann BE, Fletcher MP, Gallin JI (1983) Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes. J Immunol 130:1902–1909Google Scholar
  46. Siraganian RP (1983) Histamine secretion from mast cells and basophils. Trends Pharmacol Sci 4:432–437Google Scholar
  47. Stole V (1977) Mechanism of regulation of adenylate cyclase activity in human polymorphonuclear leukocytes by calcium, guanosyl nucleotides, and positive effectors. J Biol Chem 252:1901–1907Google Scholar
  48. Tallarida RJ, Jacob LS (1987) pA2 analysis I: Schild plot. In: Tallarida RJ, Jacob LS (eds) Manual of pharmacologic calculations with computer programs. 2nd edn Springer, Berlin Heidelberg New York, pp 53–56Google Scholar
  49. Warner JA, Yancey KB, McGlashan DW (1987) The effect of pertussis toxin on mediator release from human basophils. J Immunol 139:161–165Google Scholar
  50. Ward PA, Cunningham TW, McCulloch KK, Phan SH, Powell J, Johnson KJ (1988) Platelet enhancement of O2 responses in stimulated human neutrophils. Identification of platelet factor as adenine nucleotide. Lab Invest 58:37–47Google Scholar
  51. Weishaar RE (1987) Multiple molecular forms of phosphodiesterase: An overview. J Cyclic Nucleotide Protein Phosphor Res 11:463–472Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Rahel Burde
    • 1
  • Roland Seifert
    • 1
  • Armin Buschauerz
    • 2
  • Günter Schultz
    • 1
  1. 1.Institut für PharmakologieFreie Universität BerlinBerlin 33
  2. 2.Institut für PharmazieFreie Universität BerlinBerlin 33

Personalised recommendations